RVNC is currently covered by 10 analysts with average potential upside of $13.38 (61.59%) backed by 60 price targets and 88 ratings. Documented since 03-Mar-2014. Analyst's average stock valuation to be materialised ratio is 46.86% with an average time for price targets to be met of 208.73 days.
Most recent stock forecast was given by BALAJI PRASAD from BARCLAYS on 01-Mar-2023.
Highest price target for RVNC is 35, Lowest price target is 14, average price target is 24.5.
Currently, out of the existing stock ratings of RVNC - 30 which are a Buy (85.71%), 5 which are a Hold (14.29%)
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Buy
40
$8.61 (27.43%)
37
28 days ago
6/9 (66.67%)
$9.88 (50.63%)
428
Buy
40
$8.61 (27.43%)
38
28 days ago
3/10 (30%)
$13.16 (61.12%)
322
Buy
42
$10.61 (33.80%)
29
28 days ago
6/7 (85.71%)
$6.08 (29.50%)
277
Buy
40
$8.61 (27.43%)
29
1 months 26 days ago
1/8 (12.5%)
$12.38 (49.70%)
328
Hold
26
$-5.39 (-17.17%)
25
2 months 5 days ago
6/8 (75%)
$4.69 (18.56%)
57
What is RVNC(Revance Therapeutics, Inc) average time for price targets to be met?
Which analyst has the current highest performing score on RVNC(Revance Therapeutics, Inc) with a proven track record?
